• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS COAGUCHEK ® XS SYSTEM; PROTHROMBIN TIME TEST STRIPS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS COAGUCHEK ® XS SYSTEM; PROTHROMBIN TIME TEST STRIPS Back to Search Results
Catalog Number 04625374160
Device Problem High Test Results (2457)
Patient Problem Thromboembolism (2654)
Event Date 10/04/2021
Event Type  Injury  
Manufacturer Narrative
Initial reporter occupation is patient/consumer.The meter and test strips were requested for investigation; however, the test strips in use at the time of the blood clots are no longer available.The meter and test strips from the time of the comparisons in jan and feb 2022 (lot 54974523) were provided for investigation where they were tested using retention controls.Testing results (qc range = 2.4 - 3.6 inr): qc 1: 2.9 inr, qc 2: 3.0 inr, and qc 3: 3.0 inr.The obtained qc values were in the allowed range of the used combination strip lot - qc lot.All measurements were without error messages.The results alleged by the customer were observed in the meter¿s patient result memory.On a regular basis, coaguchek strips of lots currently valid in the market are tested as part of routine retention testing and results have passed the internal inspection.Per product labeling, "coaguchek uses human recombinant thromboplastin.Therefore, the comparability to other human recombinant thromboplastins is best, whereas higher deviations can occur with other thromboplastins.However, those higher differences between thromboplastins of different (rabbit, bovine based) origin are not a coaguchek specific issue.Similar differences can be observed when a human recombinant thromboplastin-based laboratory method is compared against several other (rabbit, bovine-based) laboratory methods." the investigation did not identify a product problem.The cause of the event could not be determined.
 
Event Description
On (b)(6) 17-feb-2022 we received an allegation that coaguchek xs meter serial number (b)(4) using strip lot 54974523 with expiration date 31-jan-2023 was not reading correctly when compared to an unknown laboratory method in (b)(6) 2022 and (b)(6) 2022.It was reported that the patient's therapeutic range used to be 2.5 - 3.5 inr but due to blood clots allegedly occurring in (b)(6) 2021 and (b)(6) 2021, the patient's therapeutic range was reportedly increased to 3.0 - 3.5 inr.The first alleged blood clot was identified on (b)(6) 2021 and the second alleged blood clot was identified on 08-sep-2021.The test strip lot number used in sep-2021 and oct-2021 was not known.This medwatch will cover the second alleged blood clot identified on (b)(6) 2021.Refer to medwatch with patient identifier (b)(6) for information on the first alleged blood clot identified on (b)(6) 2021 and medwatch with patient identifier (b)(6) for the meter to lab comparison results from (b)(6) 2022 and (b)(6) 2022.The meter results prior to the blood clot on 04-oct-2021: on 22-sep-2021 the meter result was 4.6 inr.The patient believes her warfarin dose was changed but does not know what change was made.On 29-sep-2021 the meter result was 4.2 inr.On 04-oct-2021 the alleged second clot was identified.The laboratory result at this time was reportedly 3.2 inr.The patient reportedly starting taking aspirin after the 2nd blood clot.On 08-oct-2021 the meter result was 3.9 inr.The patient's warfarin dose is reportedly based on the meter results unless there is a lab result available from the same day.If a lab result is available from the same day, the patient's warfarin dose is reportedly adjusted based on the laboratory results.The patient could not remember what specific adjustments were made prior to the blood clot in (b)(6) 2021.On 16-dec-2021 the patient had another tee scope performed and the shadowing observed before was reportedly gone.The patient reportedly used to test once per week, but, has "had to test more frequently at times due to the issues she has had.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
COAGUCHEK ® XS SYSTEM
Type of Device
PROTHROMBIN TIME TEST STRIPS
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
Manufacturer (Section G)
ROCHE DIAGNOSTICS GMBH
sandhoferstrasse 116
na
mannheim (baden-wurttemberg) 68305
GM   68305
Manufacturer Contact
michael leslie
9115 hague road
na
indianapolis, IN 46250
3175214343
MDR Report Key13804416
MDR Text Key292519620
Report Number1823260-2022-00746
Device Sequence Number1
Product Code GJS
UDI-Device Identifier00365702127104
UDI-Public00365702127104
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K062925
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer
Reporter Occupation Other
Type of Report Initial
Report Date 03/17/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/18/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Catalogue Number04625374160
Device Lot NumberASKU
Was Device Available for Evaluation? No
Date Manufacturer Received02/17/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ASPIRIN; CLOPIDOGREL/PLAVIX; CYCLOBENZAPRINE; DELOXITINE/CYMBALTA; LEVOTHYROXINE; VITAMIN D; WARFARIN
Patient Outcome(s) Hospitalization; Other;
Patient Age49 YR
Patient SexFemale
Patient Weight109 KG
-
-